Evaluating Low AMH in Clinical Practice: Diagnostic Protocols and IVF Prognosis for Patients in Dubai

Anti-Müllerian Hormone (AMH) is one of the most widely discussed serum biomarkers in modern reproductive endocrinology. However, it is also among the most frequently misconstrued. Patients presenting to reproductive medicine clinics in Dubai often interpret a low AMH reading as a definitive diagnosis of total infertility or an absolute barrier to successful In Vitro Fertilization (IVF). From a physiological standpoint, this interpretation is incorrect. AMH functions primarily as a quantitative surrogate marker of the recruitable follicular pool; it does not directly measure intrinsic oocyte quality or predict spontaneous monthly fecundity.

This article reviews the biological mechanisms of AMH, clarifies the distinction between oocyte quantity and developmental competence, analyzes realistic IVF outcome metrics under diminished ovarian reserve, and outlines evidence-based protocol options evaluated for low-responder cohorts.

What is Anti-Müllerian Hormone (AMH) and What Does It Measure?

Anti-Müllerian Hormone (AMH) is a glycoprotein secreted by granulosa cells of preantral and small antral follicles. It serves primarily as a quantitative surrogate marker for the recruitable follicular pool rather than a direct index of egg quality or spontaneous fertility.

What is the biological function of Anti-Müllerian Hormone (AMH) in female reproductive physiology?

Anti-Müllerian Hormone is a dimeric glycoprotein belonging to the transforming growth factor-beta (TGF-β) superfamily, secreted primarily by the granulosa cells of preantral and small antral follicles (approximately 2–9 mm in diameter) within the ovary. Its primary physiological role is to inhibit the initial recruitment of primordial follicles into the growing pool and to modulate the sensitivity of antral follicles to Follicle-Stimulating Hormone (FSH).

AMH correlates with the pool of growing follicles and helps predict ovarian response to Controlled Ovarian Stimulation (COS) (von Wolff & Nawroth, 2020). AMH can usually be measured on most days of the cycle, although biological and assay-related variation exists. Clinical consensus confirms that serum AMH concentrations reflect the relative size of the growing follicular pool, providing an indirect numerical estimate of the remaining reserve within the ovarian cortex.

However, serum AMH does not serve as a direct index of oocyte structural integrity, chromosomal normality, or monthly conception probability in non-IVF cycles (Steiner et al., 2017). A low AMH value indicates that fewer follicles are currently available for cyclic recruitment during controlled ovarian stimulation.

How does oocyte quantity differ from oocyte quality in reproductive medicine?

Oocyte quantity refers to the total number of recruitable follicles present in the ovaries at a given time point, measured via surrogate markers such as serum AMH and ultrasound-based Antral Follicle Count (AFC). In contrast, oocyte quality refers to the developmental competence of the egg—specifically its capacity to undergo normal meiotic segregation, complete fertilization, sustain blastocyst development, and yield a chromosomally normal (euploid) embryo.

While diminished ovarian reserve (low AMH/AFC) reduces the absolute number of oocytes retrieved during a stimulation cycle, current evidence confirms that age is one of the strongest predictors of oocyte and embryo chromosomal competence; low reserve primarily limits the number of opportunities per cycle (Practice Committee of the ASRM, 2020).

Is IVF Possible with Low AMH? Clinical Reality vs. Patient Misconceptions

IVF remains an appropriate treatment pathway for patients with low AMH levels because diminished ovarian reserve primarily affects the number of oocytes retrieved per cycle rather than the intrinsic chromosomal competence of individual oocytes or the implantation potential of embryos derived from them. However, low AMH per se, as an isolated finding, is not an indication for IVF.

Can a patient achieve an IVF pregnancy with low AMH levels?

IVF treatment remains a clinical option for patients presenting with low serum AMH levels or diminished ovarian reserve. While low AMH is associated with a lower average yield of retrieved oocytes per stimulation cycle, it does not prevent the maturation of developmentally competent eggs or preclude implantation when a viable embryo is available.

Clinical evidence demonstrates that even in cases of diminished reserve, patients may produce viable embryos when managed with individualized ovarian stimulation protocols (von Wolff & Nawroth, 2020; Xu et al., 2019). The key clinical challenge is the reduced mathematical probability of obtaining a large selection of embryos within a single cycle.

Consequently, clinical management focuses on optimizing protocol efficiency, managing cycle cancellation risks, and, where clinically appropriate, discussing individual options for sequential embryo banking.

How does maternal age modify IVF prognosis in patients with low AMH?

Maternal chronological age is a primary independent determinant of oocyte chromosomal normality and live birth potential, significantly modifying the clinical outlook for patients with low AMH. A younger patient with low AMH presents a different prognostic profile than an older patient with identical biomarker values.

To standardize the management of low-responder cohorts, the POSEIDON (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) criteria categorize patients based on age, ovarian reserve markers, and previous stimulation response (Alviggi et al., 2016):

• POSEIDON Group 3 (Age < 35 years, Low Reserve): Serum AMH < 1.2 ng/mL and/or AFC < 5. Despite retrieving fewer oocytes, these younger patients typically retain a higher expected euploidy potential than older age groups. Once a transferable euploid embryo is available, age remains a key determinant, but the cumulative probability of obtaining such an embryo may be lower when ovarian reserve is reduced.
• POSEIDON Group 4 (Age ≥ 35 years, Low Reserve): Serum AMH < 1.2 ng/mL and/or AFC < 5. These patients face a dual consideration: reduced quantitative yield combined with an age-related increase in oocyte meiotic non-disjunction (lower euploidy rates). Clinical strategies in this group often evaluate multiple stimulation cycles to attempt to obtain a viable euploid blastocyst for transfer.

Understanding IVF Success Rates for Patients with Low AMH

IVF success rates for low AMH patients depend primarily on age-related embryo quality and cumulative live birth rates across pooled cycles, rather than single-cycle oocyte yield or surrogate laboratory metrics.

What is the difference between surrogate stimulation markers and primary clinical outcomes in IVF?

In reproductive medicine, clinical literature distinguishes strictly between surrogate endpoint markers and definitive primary clinical outcomes. Conflating these categories can lead to inaccurate prognostic assumptions.

• Surrogate Markers (Quantitative Intermediate Endpoints): Total oocyte yield, mature Metaphase II (MII) count, fertilization rate, and number of day-3 or day-5 embryos. Serum AMH correlates with these parameters.
• Primary Clinical Outcomes (Therapeutic Goals): Sustained Clinical Pregnancy Rate (CPR), Implantation Rate (IR), and Live Birth Rate (LBR) per start or per embryo transfer.

Data compiled across ESHRE and ASRM consensus guidelines demonstrate that while serum AMH predicts the surrogate endpoint of oocyte yield, its independent predictive value for Live Birth Rate per embryo transfer is limited once a transferable embryo is obtained (ESHRE Guideline Group, 2019).

What factors dictate cumulative live birth rates (CLBR) in low-responder patients?

Cumulative live birth rate refers to the probability of at least one live birth after all fresh and frozen embryo transfers arising from one ovarian stimulation cycle. Definitions vary between studies and clinics, so outcome reporting should specify the denominator used. CLBR is governed by several interacting variables:

• Maternal Chronological Age: Influences the proportion of collected oocytes capable of forming euploid blastocysts.
• Total Cumulative Oocyte Yield: While single-cycle yield may be modest (e.g., 1–4 oocytes), accumulating oocytes or embryos over sequential cycles increases the cumulative probability of identifying a euploid embryo.
• Uterine & Endometrial Factors: Cavitary conditions (e.g., submucosal fibroids, endometrial polyps) should be evaluated when clinically indicated to ensure an appropriate uterine environment prior to transfer.

Individualized Stimulation Approaches in Patients with Low AMH

No single ovarian stimulation protocol has been proven superior for every patient with low AMH or a low expected ovarian response. Protocol selection is individualized according to age, AFC, prior response, treatment urgency, safety considerations, and patient preferences.

What ovarian stimulation options are evaluated for low-responder patients?

High-dose stimulation protocols often reach a physiological ceiling in poor responders, where increasing daily gonadotropin doses (e.g., beyond 300–450 IU/day of recombinant FSH) may fail to recruit additional follicles while increasing financial and physical burden. Clinical options focus on optimizing follicular synchrony and recruitment efficiency on an individual basis.

• GnRH Antagonist with Luteal Estrogen Priming: Luteal estrogen priming is used in some clinics to support follicular synchronization in selected patients, although its effect on live birth outcomes remains uncertain (Reynolds et al., 2013).
• Mild / Mini-IVF Protocols: Mild-stimulation approaches may be discussed for selected patients, particularly where medication burden, cost, or previous poor response are relevant. They should not be assumed to increase the number of oocytes or live birth rates for every patient (von Wolff & Nawroth, 2020).
• Double Stimulation (DuoStim): DuoStim may be considered when time is limited and rapid oocyte or embryo accumulation is a priority. It usually requires a freeze-all strategy, and evidence that it improves cumulative live birth rates compared with consecutive conventional cycles remains limited (Vaiarelli et al., 2018).

How are embryo accumulation strategies evaluated in low-responder cohorts?

For patients yielding 1–3 oocytes per cycle, immediate fresh transfer may limit the opportunity for extended culture to the blastocyst stage or preimplantation genetic testing.

Oocyte or embryo accumulation may be discussed when repeated cycles yield a small number of oocytes. The potential benefit of creating a larger embryo cohort should be weighed against treatment duration, cost, physical burden, and the possibility of earlier transfer. PGT-A may be considered in selected cases based on clinical indications, but it does not guarantee a live birth.

Individualized Treatment Planning

Translating low AMH findings into a clinical management plan requires a comprehensive diagnostic evaluation rather than relying on an isolated serum value. An individualized treatment plan integrates multiple clinical factors to determine the path forward.

• Comprehensive Biomarker Integration: Evaluating serum AMH alongside transvaginal Antral Follicle Count (AFC) and baseline Day 2–3 FSH/estradiol levels to establish a clearer picture of ovarian response capacity.
• Age-Adjusted Expectation Management: Differentiating between numerical yield constraints and true reproductive potential, ensuring younger patients with low AMH understand that their intrinsic egg quality remains a key asset.
• Customized Protocol Selection: Evaluating stimulation frameworks—whether GnRH antagonist with priming, mild IVF, or DuoStim—that match the patient's specific physiological profile rather than relying on uniform high-dose protocols.
• Pre-Conception Optimization: Addressing overall health, metabolic factors, lifestyle considerations, and male partner parameters to support optimal conditions for fertility evaluation and treatment planning.

Frequently Asked Questions

Is IVF possible with an AMH level below 0.5 ng/mL?

Yes. An AMH level below 0.5 ng/mL is often associated with a lower number of retrieved oocytes and a higher risk of cycle cancellation, although individual response can vary substantially. Provided mature oocytes can be retrieved and fertilized, embryo development and live birth remain achievable, particularly in younger patients (Xu et al., 2019).

Does a low AMH level mean that egg quality is compromised?

No. AMH measures follicular quantity (the size of the recruitable egg pool), not oocyte quality. Chromosomal integrity and developmental potential are governed primarily by maternal chronological age. A 30-year-old patient with low AMH will generally produce fewer eggs than average, but a significant proportion of those eggs typically remain chromosomally normal (euploid).

Can supplements or medications raise AMH levels before starting IVF?

There is currently no scientific consensus demonstrating that dietary supplements or medications can permanently restore the primordial follicle pool or raise serum AMH in a clinically meaningful way. Management focuses on optimizing the recruitment and development of the existing follicular pool through tailored medical stimulation protocols rather than delaying treatment.

Is donor egg IVF mandatory (the only option?) for patients with low AMH?

No, donor egg IVF is not mandatory for patients with low AMH. Donor oocytes may be discussed as one of several reproductive options when repeated treatment with own oocytes has not resulted in transferable embryos or when the expected chance of success with own oocytes is very low. It is never an automatic consequence of a low AMH result. Treatment decisions are made collaboratively based on age, response history, and individual patient preferences.

References

• Alviggi C, Andersen CY, Buehler K, et al. A new more detailed stratification of low responders to ovarian stimulation: The POSEIDON concept. Fertil Steril. 2016;105(6):1452-1453. doi:10.1016/j.fertnstert.2016.02.005. PMID: 26945884.
• ESHRE Guideline Group on Ovarian Stimulation, Bosch E, Broer S, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open. 2020;2020(2):hoaa009. doi:10.1093/hropen/hoaa009. PMID: 32395637.
• Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114(6):1151-1157. doi:10.1016/j.fertnstert.2020.09.134. PMID: 33280722.
• Reynolds KA, Omurtag KR, Jimenez PT, et al. Cycle outcomes associated with luteal estradiol priming in poor responders undergoing IVF. Hum Reprod. 2013;28(11):2981-2987. doi:10.1093/humrep/det333. PMID: 23975709.
• Steiner AZ, Jukic AM, Vance RB, et al. Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age. JAMA. 2017;318(14):1367-1376. doi:10.1001/jama.2017.14588. PMID: 29049102.
• Vaiarelli A, Cimadomo D, Trabucco E, et al. Double Stimulation in the Same Menstrual Cycle (DuoStim) to Maximize the Number of Oocytes Retrieved in Poor Prognosis Patients. J Vis Exp. 2018;(139):57709. doi:10.3791/57709. PMID: 30272260.
• von Wolff M, Nawroth F, eds. Fertility Preservation in Oncological and Non-Oncological Diseases: A Practical Guide. Springer Nature Switzerland AG; 2020. ISBN 978-3-030-47567-3.
• Xu H, Zhang Y, Zhang J, et al. Cumulative live birth rates according to ovarian reserve in women undergoing IVF/ICSI. Reprod Biomed Online. 2019;38(4):572-580. doi:10.1016/j.rbmo.2018.12.034. PMID: 30846287.

Disclaimer: This article is for general educational purposes only and does not constitute medical advice, formal diagnosis, or a treatment recommendation. Healthcare choices and clinical pathways must be determined in direct consultation with a licensed reproductive endocrinologist following a comprehensive, individualized medical assessment.

About the author

Dr Ewa Goncikowska, MD, PhD
Specialist in Gynaecological Endocrinology, Reproduction & Infertility